mirikizumab psoriasis
Selected indexed studies
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (JAMA, 2020) [PMID:32427307]
- Challenges and Future Trends in the Treatment of Psoriasis. (Int J Mol Sci, 2023) [PMID:37686119]
- Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials. (Inflammopharmacology, 2025) [PMID:39954188]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. (2022) pubmed
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (2020) pubmed
- Challenges and Future Trends in the Treatment of Psoriasis. (2023) pubmed
- Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials. (2025) pubmed
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (2021) pubmed
- Does Mirikizumab benefit patients with plaque psoriasis? a systematic review and meta-analysis. (2026) pubmed
- Efficacy and safety of mirikizumab (LY3074828) in chronic plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. (2025) pubmed
- Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study. (2023) pubmed
- Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). (2022) pubmed
- Mirikizumab for Chronic Plaque Psoriasis: A Systematic Review and Meta-Analysis. (2024) pubmed